Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions.

about

Plant-Derived Anticancer Agents: Lessons from the Pharmacology of Geniposide and Its Aglycone, Genipin.MAPK reliance via acquired CDK4/6 inhibitor resistance in cancer.ERα-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancer.

P2860

Q52723792-A483B487-677D-47F3-AF0A-C2272F27DF8E Q53685801-87BC652F-1283-468B-A0BC-BE79E62FFCE3 Q55426345-986BA3B7-3511-49DF-A955-85A0EDB49121

P2860

Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions.

Item

http://www.wikidata.org/entity/Q47316489

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions.

@en

Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions.

@nl

type

Item

label

Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions.

@en

Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions.

@nl

prefLabel

Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions.

@en

Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions.

@nl

P1476

Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions

@en

P2093

Rachel M Layman

http://www.w3.org/2001/XMLSchema#string

P2860

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells

Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance

Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.

Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.

Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers

Targeting CDK4 and CDK6: From Discovery to Therapy

P2888

s11523-017-0541-2

P304

21-38

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S11523-017-0541-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Khandan Keyomarsi

Smruthi Vijayaraghavan

Stacy Moulder

P577

2018-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29218622

http://www.w3.org/2001/XMLSchema#string

Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions.

about

P2860

P2860

Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698